Biden administration makes opening offers in Medicare drug price negotiations; Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio

Taking stock of the drug industry, from the lab to the medicine chest

February 1, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Scott Olson/Getty Images STAT+ | Biden administration makes opening offers in Medicare drug price negotiations Medicare begins its drug price negotiation program today, with final prices to be set by Sept. 1 and to take effect in 2026. By Rachel Cohrs STAT+ | Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio Genetic treatments are a huge medical advance, but can these transformational (and expensive) products become a profitable business? By Adam Feuerstein STAT+ | Obscure vertigo drug could bring rare hope for patients with devastating neuron disease After years of failure, a molecule looks poised to become the first U.S.-approved drug for Niemann-Pick, a fatal genetic disease. By Jason Mast Adobe STAT+ | Judge skeptical of arguments against Medicare drug price negotiation A judge grilled industry lawyers over their contention that Medicare's drug price negotiation program is unconstitutional. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser